Freedom of Information
- Title
- Breast cancer
- Reference Number
- RF24-112
- Request Details
-
How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
• Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
• Abemaciclib + Fulvestrant
• Alpelisib + Fulvestrant
• Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
• Atezolizumab +Nab-paclitaxel/Paclitaxel
• Capecitabine as a single agent
• Eribulin as a single agent or in combination
• Everolimus + Exemestane
• Fulvestrant as a single agent
• Lapatinib
• Neratinib
• Parp Inhibitors (Olaparib/Talazoparib)
• Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
• Palbociclib + Fulvestrant
• Pembrolizumab
• Platinum (e.g. carboplatin or cisplatin) as a single agent
• Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
• Ribociclib + Fulvestrant
• Sacituzumab Govitecan
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
• Taxane and/or Anthracycline in combination
• Trastuzumab as a single agent or in combination
• Trastuzumab emtansine
• Transtuzumab deruxtecan
• Any other active systemic anti-cancer therapy -
Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.
-
- Response
-
- rf24-112-response.pdf
- Date of Disclosure
- 20/02/2024